Automated Sarcopenia Assessment on CT for Predicting Participant Survival and Toxicity in Early‐Phase Immunotherapy Trials
JCSM Communications · 2026-07 · 9 (2)
DOI: 10.1002/rco2.70055 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCSM Communications, online erschienen am 11.11.2026. Verfasst von Mitchell Chen und 12 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Survival prediction in early‐phase trial participants is crucial for ensuring only those with sufficient life expectancy are offered experimental therapies. This study evaluated automated CT‐derived sarcopenia metrics for predicting overall survival (OS) and clinically significant treatment‐related adverse events (CS‐AE) in early‐phase immunotherapy trials.
Methods
Participants with cancers of various primaries from early‐phase immunotherapy trials at two centres were included (Imperial College London, United Kingdom: n = 53, male:female (M:F) = 23:30, age (mean ± standard deviation): 59.4 ± 15.4; Humanitas Cancer Centre, Milan, Italy: n = 58, M:F = 32:26, age (mean ± standard deviation): 64.8 ± 11.6). The most common primary was ovarian (18.9%) in London and hepatocellular (31.0%) in Milan . 58.5% and 32.8% received single‐agent therapy in London and Milan , respectively and the remainder combination therapy. We computed sarcopenia metrics, including skeletal muscle area (SMA) and mean Hounsfield unit (MHU), using in‐house AI software, SarcAI , imputed a sex‐specific composite sarcopenia score (CSS) using Cox regression, based on height‐adjusted SMA, MHU and body mass index (BMI), and benchmarked their predictive performance for OS and CS‐AE.
Results
Overall, 66 prognostic events were observed, with a 1‐year mortality rate of 86.8% (95% confidence interval [CI]: 73.7%–93.4%) in London and 35.7% (95% CI: 21.9%–47.1%) in Milan . SMA predicted 1‐year OS in female patients (area under the receiver operating characteristic curve 0.75, 95% CI [0.51, 0.98]). MHU predicted 90‐day OS (0.76 [0.54, 0.98]) and CSS 1‐year OS (0.70 [0.53, 0.87]). Both exceeded the prognostic performance of performance status (PS) in Milan (1‐year: 0.61 [0.43, 0.80]; 90‐day: 0.56 [0.13, 0.98]). SMA and CSS showed borderline significant prediction for CS‐AE (SMA: 0.64 [0.44, 0.84]; CSS: 0.66 [0.47, 0.86]), outperforming PS (0.59 [0.41, 0.77]).
Conclusions
AI‐based CT sarcopenia metrics showed associations with OS and CS‐AE in early‐phase immunotherapy trial participants, supporting further investigation into their clinical predictive utility.
Zitieren
APA
Chen, M., Copley, S. J., D'Alessio, A., Simonelli, M., Maleki, A., Dai, Z., Wang, Y., Korolewicz, J. A., Losurdo, A., Barigazzi, C., Rockall, A. G., Pinato, D. J., & Aboagye, E. O. (2026). Automated Sarcopenia Assessment on CT for Predicting Participant Survival and Toxicity in Early‐Phase Immunotherapy Trials. JCSM Communications, 9(2). https://doi.org/10.1002/rco2.70055
Vancouver
Chen M, Copley SJ, D'Alessio A, Simonelli M, Maleki A, Dai Z, et al. Automated Sarcopenia Assessment on CT for Predicting Participant Survival and Toxicity in Early‐Phase Immunotherapy Trials. JCSM Communications. 2026;9(2). doi:10.1002/rco2.70055
BibTeX
@article{Chen2026,
author = {Chen, Mitchell and Copley, Susan J. and D'Alessio, Antonio and Simonelli, Matteo and Maleki, Aryan and Dai, Zhenwu and Wang, Yuxi and Korolewicz, James A. and Losurdo, Agnese and Barigazzi, Chiara and Rockall, Andrea G. and Pinato, David J. and Aboagye, Eric O.},
title = {Automated Sarcopenia Assessment on CT for Predicting Participant Survival and Toxicity in Early‐Phase Immunotherapy Trials},
journal = {JCSM Communications},
year = {2026},
volume = {9},
number = {2},
doi = {10.1002/rco2.70055}
}
EUVIMED